Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

被引：7

作者：

Costa, Luciano J. ^{[1
]}

Stadtmauer, Edward A. ^{[2
]}

Morgan, Gareth ^{[3
]}

Monohan, Gregory ^{[4
]}

Kovacsovics, Tibor ^{[5
]}

Burwick, Nicholas ^{[6
]}

Jakubowiak, Andrzej ^{[7
]}

Kaufman, Jonathan L. ^{[8
]}

Mobasher, Mehrdad ^{[9
]}

Freise, Kevin J. ^{[10
]}

Ross, Jeremy A. ^{[10
]}

Pesko, John ^{[10
]}

Munasinghe, Wijith ^{[10
]}

Gudipati, Saketh ^{[10
]}

Mudd, Sarah ^{[10
]}

Bueno, Orlando ^{[10
]}

Kumar, Shaji K. ^{[11
]}

机构：

[1] Univ Alabama, Vestavia, AL USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

[4] Univ Kentucky, Lexington, KY USA

[5] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[6] VA Puget Sound Hlth Care Syst, Seattle, WA USA

[7] Univ Chicago, Chicago, IL 60637 USA

[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[9] Genentech Inc, San Francisco, CA USA

[10] AbbVie Inc, N Chicago, IL USA

[11] Mayo Clin, Div Hematol, Rochester, MN USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-117026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

303

引用

页数：3

共 50 条

[41] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
Biran, Noa
Siegel, David
Berdeja, Jesus G.
Raje, Noopur
Cornell, Robert Frank
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy S.
Landgren, Ola
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
[42] Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng
H Goldschmidt
M A Dimopoulos
P Moreau
D Joshua
A Palumbo
T Facon
H Ludwig
L Pour
R Niesvizky
A Oriol
L Rosiñol
A Suvorov
G Gaidano
T Pika
K Weisel
V Goranova-Marinova
H H Gillenwater
N Mohamed
S Feng
S Aggarwal
R Hájek
[J]. Leukemia, 2017, 31 : 1368 - 1374
[43] Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Moreau, Philippe
Chanan-Khan, Asher Alban Akmal
Roberts, Andrew Warwick
Agarwal, Amit
Facon, Thierry
Kumar, Shaji
Touzeau, Cyrille
Diehl, Susan
Cordero, Jaclyn
Ross, Jeremy A.
Munasinghe, Wijith
Zhu, Ming
Salem, Ahmed H.
Leverson, Joel
Maciag, Paulo Cesar
Verdugo, Maria E.
Harrison, Simon J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[44] Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency
Badros, A. Z.
Vij, R.
Martin, T.
Zonder, J. A.
Wong, A. F.
Woo, T.
Boussina, K.
Wang, Z.
Niesvizky, R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[45] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse
Weisel, Katja
Geils, George F.
Karlin, Lionel
Mollee, Peter
Chung, Tae-Hoon
Min, Chang-Ki
Sunami, Kazutaka
Goldrick, Amanda
Fang, Belle
Fowler, Jessica
Mateos, Maria-Victoria
[J]. BLOOD, 2020, 136
[46] A PHASE 1-2 STUDY OF CARFILZOMIB-POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE
Bringhen, S.
Mina, R.
Liberati, A. M.
Belotti, A.
Gaidano, G.
Bertazzoni, P.
Stocchi, R.
Ruggeri, M.
Ribolla, R.
Di Sano, C.
Patriarca, F.
Bernardini, A.
De Paoli, L.
Cafro, A. M.
Palumbo, A.
Sonneveld, P.
Boccadoro, M.
[J]. HAEMATOLOGICA, 2017, 102 : 25 - 25
[47] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, Jatin J.
Stadtmauer, Edward A.
Abonour, Rafat
Cohen, Adam D.
Bensinger, William I.
Gasparetto, Cristina
Kaufman, Jonathan L.
Lentzsch, Suzanne
Vogl, Dan T.
Gomes, Christina L.
Pascucci, Natalia
Smith, David D.
Orlowski, Robert Z.
Durie, Brian G. M.
[J]. BLOOD, 2015, 126 (20) : 2284 - 2290
[48] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis
Facon, Thierry
Moreau, Philippe
Martin, Thomas G.
Spicka, Ivan
Oriol, Albert
Koh, Youngil
Lim, Andrew
Mikala, Gabor
Rosinol, Laura
Yagci, Munci
Cavo, Michele
Yong, Kwee
Risse, Marie-Laure
Asset, Gaelle
Schwab, Sandrine
Martinez, Gracia
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S420 - S420
[49] ISATUXIMAB UPDATES FOR NURSES: ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS (IKEMA)
Wilmoth, Jenal
Marion, Sylvia
Kellam, Christine
[J]. ONCOLOGY NURSING FORUM, 2021, 48 (02)
[50] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
Jakubowiak, Andrzej J.
Richardson, Paul G.
Zimmerman, Todd
Alsina, Melissa
Kaufman, Jonathan L.
Kandarpa, Malathi
Kraftson, Stephanie
Ross, Charles W.
Harvey, Colleen
Hideshima, Teru
Sportelli, Peter
Poradosu, Enrique
Gardner, Lesa
Giusti, Kathy
Anderson, Kenneth C.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480

← 1 2 3 4 5 →